Literature DB >> 19031123

[Hepatotoxicity by antibiotics: update in 2008].

M Robles1, R J Andrade.   

Abstract

Although antibiotics are the most commonly incriminated drugs in instances of hepatotoxicity in medical literature. However, it is mainly due to its wide prescription and the absolute risk of hepatotoxicity related to antibiotic use is thought to be low. Nevertheless, among the different penicillins, amoxicillin-clavulanate is the single leading drug involved in hepatotoxicity in cohorts of patients with drug-induced liver injury (DILI), representing between 12.8% to 14% of the cases. It is the most frequent cause of hospitalization for DILI. The incidence of amoxicillin-clavulanate induced hepatotoxicity has been estimated to be 9.91 per 100,000 users and its clinical presentation varies, the type of injury strongly influenced by age, with the hepatocelullar pattern predominating in younger patients and the cholestatic/mixed ones in older subjects. Among macrolides, erythromycin is a classical example of drug capable of inducing cholestatic injury. Recently, concern has arisen regarding telithromycin, a new generation macrolide, is hepatotoxic came from the identification of several cases of DILI related to this drug, with a typical signature, including abrupt commence of fever, abdominal pain, jaundice and ascites in some cases. Tetracyclines, especially in intravenous high doses, may be associated with dose-dependent microvesicular steatosis, and minocycline has been involved in an autoimmune like type I hepatitis. Quinolones, in spite of their extensive use in patients with cirrhosis and biliary infections, have been very rarely associated with hepatotoxicity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19031123

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


  5 in total

Review 1.  Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components.

Authors:  Alison E Barnhill; Matt T Brewer; Steve A Carlson
Journal:  Antimicrob Agents Chemother       Date:  2012-05-21       Impact factor: 5.191

2.  A case of ceftriaxone-induced liver injury and literature review.

Authors:  Matteo Guarino; Benedetta Perna; Alessandra Pastorelli; Paolo Bertolazzi; Giacomo Caio; Martina Maritati; Roberto De Giorgio; Carlo Contini
Journal:  Infez Med       Date:  2022-06-01

3.  Ceftriaxone-induced toxic hepatitis.

Authors:  Erdal Peker; Eren Cagan; Murat Dogan
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

Review 4.  Safety profile of the respiratory fluoroquinolone moxifloxacin: comparison with other fluoroquinolones and other antibacterial classes.

Authors:  Françoise Van Bambeke; Paul M Tulkens
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 5.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.